Category: 103505-54-0

Simple exploration of 103505-54-0

103505-54-0, As the paragraph descriping shows that 103505-54-0 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103505-54-0,[2,2′-Bipyridine]-6,6′(1H,1’H)-dione,as a common compound, the synthetic route is as follows.

(1) 6,6′-Dihydroxy-2,2′-bipyridine (6DHBP) (0.0379 g, 0.20 mmol) under a nitrogen atmosphereAnd phenyl ruthenium chloride dimer [(eta6-C6H6)RuCl2]2 (0.050 mg, 0.10 mmol) was added to a 50 mL two-necked flask, 20 mL of anhydrous methanol was added, and the temperature was raised to 60 C, and the reaction was stirred in the dark. After 20 h, after completion of the reaction, the mixture was cooled to room temperature, and the reaction mixture was filtered to remove insoluble materials, and the filtrate was collected. The solvent was distilled off under reduced pressure and dried in vacuo.Obtained 0.0644 g of metal ruthenium complex [(eta6-C6H6)Ru(6,6′-(OH)2-bpy)Cl]Cl catalyst.

103505-54-0, As the paragraph descriping shows that 103505-54-0 is playing an increasingly important role.

Reference£º
Patent; Dalian University of Technology; Wang Wanhui; Wang Kanglei; Bian Fei; Liu Xin; Bao Ming; (10 pag.)CN109928873; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

New learning discoveries about 103505-54-0

The synthetic route of 103505-54-0 has been constantly updated, and we look forward to future research findings.

103505-54-0, [2,2′-Bipyridine]-6,6′(1H,1’H)-dione is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

As shown in Synthesis Scheme 1-a, to a dicationic Cp * iridium-aco complex (407.8 mg, 0.60 mmol) was added 6,6′-dihydroxy-2,2′-bipyridine ligand (113.8 mg, 0 , 60 mmol) was allowed to act in an aqueous solvent (12 mL) to obtain a complex A (yield 93%). Subsequently, neutral iridium complex 1 was obtained by allowing sodium t-butoxide (211.4 mg, 2.2 mmol) to react with complex A (915.0 mg, 1.1 mmol) in an aqueous solvent (30 mL) (Yield 84%)., 103505-54-0

The synthetic route of 103505-54-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; KANTO CHEM CO INC; YAMAGUCHI, RYOHEI; FUJITA, KENICHI; (38 pag.)JP2015/83544; (2015); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Downstream synthetic route of 103505-54-0

The synthetic route of 103505-54-0 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103505-54-0,[2,2′-Bipyridine]-6,6′(1H,1’H)-dione,as a common compound, the synthetic route is as follows.,103505-54-0

As shown in scheme 1-b, [Cp*IrCl2]2 (458.4 mg, 0.570 mmol) was reacted with 6,6?-dihydroxy-2,2?-bipyridine ligand (250.0 mg, 1.33 mmol) in methanol solvent (8 mL), a reaction was carried out at 60 C. for 3 hours, and filtration using a glass filter was then carried out to thus give cationic complex A? (yield 74%). Subsequently, cationic complex A? (100.0 mg, 0.170 mmol) was reacted with potassium t-butoxide (38.3 mg, 0.340 mmol) in water (5 mL) at room temperature for 30 minutes while stirring, and a solid thus precipitated was filtered to thus give complex 1 (yield 64%).1H NMR (400 MHz, CD3OD) delta 7.43 (t, J=8 Hz, 2H), 6.92 (d, J=8 Hz, 2H), 6.43 (d, J=8 Hz, 2H), 1.59 (s, 15H). 13C{1H} NMR (125.8 MHz, CD3OD) delta 170.9, 157.3, 139.9, 118.1, 106.9, 88.0, 9.83. Anal. Calcd for C20H23O3N2Ir: C, 45.18; H, 4.36; N, 5.27. Found: C, 45.47; H, 4.01; N, 5.62.

The synthetic route of 103505-54-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Kanto Kagaku Kabushiki Kaisha; Yamaguchi, Ryohei; Fujita, Ken-ichi; (26 pag.)US2016/297844; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Simple exploration of 103505-54-0

As the paragraph descriping shows that 103505-54-0 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103505-54-0,[2,2′-Bipyridine]-6,6′(1H,1’H)-dione,as a common compound, the synthetic route is as follows.

Example 1 [Ru(bpy)2(66’bpy(OH)2)][PF6]2.H2O A round bottom flask containing 30 mL of 1:1 ethanol:water was degassed with argon for 30 minutes. To the flask, 0.2260 g (1.201 mmol) 66’bpy(OH)2 and 0.4843 g (0.9999 mmol) Ru(bpy)2(Cl)2 were added. The reaction mixture was heated at 80 C. under argon for 12 h. The reaction mixture turned red in color. After heating, the reaction mixture was allowed to cool to room temperature and filtered to remove any insoluble, unreacted ligand. A few drops of concentrated HCl was added to the filtrate to ensure protonation and the solution was diluted to 200 mL with water. An aqueous solution of ammonium hexafluorophosphate was added to the filtrate to precipitate the complex as the hexafluorophosphate salt. The complex was filtered and rinsed with copious amounts of water and allowed to air dry overnight. Yield: 0.5738 g (0.6309 mmol), 63%. deltaH (300 MHz, CD3CN): delta 6 8.70 (broad), delta 8.50 (d, 2H), delta 8.35 (d, 2H), delta 7.95 (m, 10H), delta 7.55 (d, 2H), delta 7.45 (t, 2H), delta 7.20 (t, 2H), delta 6.70 (d, 2H). Elem. Anal: Found: C, 39.43; N, 9.23; H, 2.89%. Calc. for RuC30N6O2H24P2F12.H2O: C, 39.62; N, 9.24; H, 2.88%.

As the paragraph descriping shows that 103505-54-0 is playing an increasingly important role.

Reference£º
Patent; The Board of Trustees of the University of Alabama; Papish, Elizabeth T.; Paul, Jared J.; Merino, Edward J.; (21 pag.)US2016/101177; (2016); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI